286 related articles for article (PubMed ID: 30081149)
21. Somatostatin receptor activity assessed by
Mapelli P; Bezzi C; Muffatti F; Ghezzo S; Baldassi F; Schiavo Lena M; Andreasi V; Canevari C; Magnani P; De Cobelli F; Gianolli L; Partelli S; Falconi M; Picchio M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2818-2829. PubMed ID: 37010579
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
[TBL] [Abstract][Full Text] [Related]
23. Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
[TBL] [Abstract][Full Text] [Related]
24. Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors.
Terra Md SBSP; Xie Md PhD H; Boland Md JM; Mansfield Md AS; Molina Md PhD JR; Roden Md AC
Hum Pathol; 2019 Dec; 94():78-85. PubMed ID: 31499081
[TBL] [Abstract][Full Text] [Related]
25. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.
Schmitt AM; Marinoni I; Blank A; Perren A
Endocr Pathol; 2016 Sep; 27(3):200-4. PubMed ID: 27456058
[TBL] [Abstract][Full Text] [Related]
26. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
27. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
28. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
29. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract][Full Text] [Related]
31. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
33. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
34. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
Casar-Borota O; Botling J; Granberg D; Stigare J; Wikström J; Boldt HB; Kristensen BW; Pontén F; Trouillas J
Am J Surg Pathol; 2017 Sep; 41(9):1238-1246. PubMed ID: 28719461
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
[TBL] [Abstract][Full Text] [Related]
36. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
37. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
[TBL] [Abstract][Full Text] [Related]
39. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
40. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
